Machine learning tools were able to identify biomarkers in blood that could enable earlier diagnosis of children with autism spectrum disorder.

Machine learning tools analyzed hundreds of proteins and identified blood biomarkers that could speed the diagnosis of autism spectrum disorder (ASD), according to a study published in PLOS One.

ASD impacts at least one out of every 59 children in the US, researchers noted. The condition is also associated with significant personal, family, and societal costs. Efforts to determine the underlying biology of ASD, as well as ASD prevention, early diagnosis, and effective treatment, are public health priorities.

Being able to identify children with autism when they’re toddlers could make a big difference, the team stated. Currently, the average age of a child diagnosed with ASD in the US is four years old.

Dig Deeper

• Machine Learning, Facebook Data Offer Insight into Schizophrenia
• Machine Learning Tool Can Detect Changes in Serotonin Levels
• Machine Learning Scans Retinal Images to Predict Alzheimer’s Disease

Diagnosis before the age of four means that a child is more likely to receive an effective, evidence-based treatment, including therapies directed at core ASD symptoms like inflexible behaviors and lack of communication skills.

Researchers have investigated many blood-based biomarker candidates, including neurotransmitters, cytokines, and markers of mitochondrial dysfunction, oxidative stress, and impaired methylation. However, because ASD is so prevalent, using machine learning to incorporate demographic and clinical data into the analysis could more powerfully examine disease status and symptom severity.

For the study, the team examined serum samples from 76 boys with ASD and 78 from typically developing boys aged between 18 months and eight years. The results showed that all nine proteins in the biomarker panel were significantly different in boys with ASD compared with typically developing boys. Researchers found that each of the nine serum proteins correlated with symptom severity.

Researchers evaluated more than 1,100 proteins using the SomaLogic protein analysis platform. The group identified a panel of nine proteins as optimal for predicting ASD using three computational methods. Researchers then evaluated the biomarker panel for quality using machine learning methods.

“The more significantly affected the child is, the higher or lower than normal the blood biomarker is,” said Dwight German, PhD, professor of psychiatry at UT Southwestern and senior author of the study.

“Ideally, there will be a day when a child is identified using blood biomarkers as being at risk for developing ASD and therapies can be started immediately. That would help the child develop skills to optimize their communication and learning.”

The team noted that future studies will need to fully validate the present findings.

“Although the sample size is acceptable for a discovery study, the data presented here are preliminary, and a larger validation study is needed to be certain of the value of the biomarker panel. Due to the increased prevalence of ASD in boys, this study only enrolled boys, which does not allow for an investigation of gender-specific differences,” researchers noted.

The researchers expect that the study will pave the way for earlier diagnosis of autism.

“The earlier we can identify children with autism, the more understanding we can gain on ways to provide support and therapies that will improve their quality of life,” said Laura Hewitson, PhD, at The Johnson Center for Child Health & Development, a multidisciplinary treatment center in Austin, Texas, that uses a unique combination of clinical care, research, and education to further the understanding of ASD and related developmental disorders.

Researchers have previously turned to AI and data analytics techniques to enable earlier autism diagnosis. A study recently published in Nature Medicine showed that a precision medicine method enabled by artificial intelligence could lead to the first biomedical screening tool for a subtype of autism.

“Our study is the first precision medicine approach to overlay an array of research and healthcare data—including genetic mutation data, sexually different gene expression patterns, animal model data, EHR data, and health insurance claims data—and then use an AI-enhanced precision medicine approach to attempt to define one of the world’s most complex inheritable disorders,” said Yuan Luo, associate professor of preventive medicine: health and biomedical informatics at the Northwestern University Feinberg School of Medicine.

The post Machine Learning Detects Biomarkers of Autism Spectrum Disorder appeared first on Artificial Intelligence.

Researchers are developing an Artificial Intelligence (AI)-based system that could help detect melanoma skin cancer earlier.

The technology employs machine-learning software to analyse images of skin lesions and provides doctors with objective data on telltale biomarkers of melanoma, which is deadly if detected too late, but highly treatable if caught early.

The AI system – trained using tens of thousands of skin images and their corresponding eumelanin and hemoglobin levels – could initially reduce the number of unnecessary biopsies, a significant health-care cost.

Changes in the concentration and distribution of eumelanin, a chemical that gives skin its colour, and hemoglobin, a protein in red blood cells, are strong indicators of melanoma.

The new system gives doctors objective information on lesion characteristics to help them rule out melanoma before taking more invasive action, according to the researchers.

“This could be a very powerful tool for skin cancer clinical decision support,” said Alexander Wong, Professor at University of Waterloo in Canada.

The technology, presented at the 14th International Conference on Image Analysis and Recognition in Montreal, Canada, could be available to doctors as early as next year.

Currently, dermatologists largely rely on subjective visual examinations of skin lesions such as moles to decide if patients should undergo biopsies to diagnose the disease.

The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on appearance alone.

“There can be a huge lag time before doctors even figure out what is going on with the patient,” Wong said.

“Our goal is to shorten that process,” Wong added.

Instead, the AI would anaylse images of the lesions, and look for telltale biomarkers of cancer that it has been taught through studying tens of thousands of images, and then it could provide doctors with objective data to make a decision.

The signs it is looking out for would include changes in the concentration and distribution of eumelanin (a chemical that gives skin its colour), and hemoglobin, both strong indicators that a melanoma is present.

The post Artificial Intelligence system to help detect skin cancer appeared first on Artificial Intelligence.